Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma

Matteo Santoni, Alessandro Conti, Camillo Porta, Giuseppe Procopio, Cora N. Sternberg, Umberto Basso, Ugo De Giorgi, Sergio Bracarda, Mimma Rizzo, Cinzia Ortega, Francesco Massari, Roberto Iacovelli, Lisa Derosa, Cristina Masini, Michele Milella, Giuseppe Di Lorenzo, Francesco Atzori, Maria Pagano, Sebastiano Buti, Rocco De VivoAlessandra Mosca, Marta Rossi, Chiara Paglino, Elena Verzoni, Linda Cerbone, Giovanni Muzzonigro, Massimo Falconi, Rodolfo Montironi, Luciano Burattini, Daniele Santini, Stefano Cascinu

Research output: Contribution to journalArticle

Abstract

Purpose: Late recurrence of renal cell carcinoma is not a rare event. In this retrospective study we investigate the clinicopathological features and the outcome of patients treated with sorafenib, sunitinib and pazopanib for late relapsing renal cell carcinoma. Materials and Methods: Data were collected from 21 Italian centers involved in the treatment of metastatic renal cell carcinoma. Late relapse was defined as more than 5 years after initial radical nephrectomy. Results: A total of 2,490 patients were screened and 269 (11%) were included in the study. First line therapy was sunitinib in 190 patients (71%), sorafenib in 58 (21%) and pazopanib in 21 (8%). Median progression-free survival was 20.0 months for sunitinib (95% CI 17.0-25.1), and 14.1 months for sorafenib (95% CI 11.0-29.0) and pazopanib (95% CI 11.2-not reported). On multivariate analysis MSKCC score and metastases to lymph nodes, liver and brain were associated with worst overall survival, while pancreatic metastases were associated with longer survival. Furthermore, age, MSKCC score and brain metastases were associated with worst progression-free survival. Conclusions: Patients with late relapsing renal cell carcinoma seem to present a characteristic pattern of metastatic spread without showing significant differences in terms of progression-free survival among sorafenib, sunitinib and pazopanib.

Original languageEnglish
JournalJournal of Urology
DOIs
Publication statusAccepted/In press - 2015

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Neoplasm Metastasis
Recurrence
Survival
Brain
Therapeutics
Nephrectomy
Multivariate Analysis
Retrospective Studies
Lymph Nodes
sorafenib
sunitinib
pazopanib
Liver

Keywords

  • Carcinoma
  • Protein-tyrosine kinases
  • Recurrence
  • Renal cell
  • Survival

ASJC Scopus subject areas

  • Urology

Cite this

Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. / Santoni, Matteo; Conti, Alessandro; Porta, Camillo; Procopio, Giuseppe; Sternberg, Cora N.; Basso, Umberto; De Giorgi, Ugo; Bracarda, Sergio; Rizzo, Mimma; Ortega, Cinzia; Massari, Francesco; Iacovelli, Roberto; Derosa, Lisa; Masini, Cristina; Milella, Michele; Di Lorenzo, Giuseppe; Atzori, Francesco; Pagano, Maria; Buti, Sebastiano; De Vivo, Rocco; Mosca, Alessandra; Rossi, Marta; Paglino, Chiara; Verzoni, Elena; Cerbone, Linda; Muzzonigro, Giovanni; Falconi, Massimo; Montironi, Rodolfo; Burattini, Luciano; Santini, Daniele; Cascinu, Stefano.

In: Journal of Urology, 2015.

Research output: Contribution to journalArticle

Santoni, M, Conti, A, Porta, C, Procopio, G, Sternberg, CN, Basso, U, De Giorgi, U, Bracarda, S, Rizzo, M, Ortega, C, Massari, F, Iacovelli, R, Derosa, L, Masini, C, Milella, M, Di Lorenzo, G, Atzori, F, Pagano, M, Buti, S, De Vivo, R, Mosca, A, Rossi, M, Paglino, C, Verzoni, E, Cerbone, L, Muzzonigro, G, Falconi, M, Montironi, R, Burattini, L, Santini, D & Cascinu, S 2015, 'Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma', Journal of Urology. https://doi.org/10.1016/j.juro.2014.07.011
Santoni, Matteo ; Conti, Alessandro ; Porta, Camillo ; Procopio, Giuseppe ; Sternberg, Cora N. ; Basso, Umberto ; De Giorgi, Ugo ; Bracarda, Sergio ; Rizzo, Mimma ; Ortega, Cinzia ; Massari, Francesco ; Iacovelli, Roberto ; Derosa, Lisa ; Masini, Cristina ; Milella, Michele ; Di Lorenzo, Giuseppe ; Atzori, Francesco ; Pagano, Maria ; Buti, Sebastiano ; De Vivo, Rocco ; Mosca, Alessandra ; Rossi, Marta ; Paglino, Chiara ; Verzoni, Elena ; Cerbone, Linda ; Muzzonigro, Giovanni ; Falconi, Massimo ; Montironi, Rodolfo ; Burattini, Luciano ; Santini, Daniele ; Cascinu, Stefano. / Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. In: Journal of Urology. 2015.
@article{aba820f8421a4792a51d72d94b954621,
title = "Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma",
abstract = "Purpose: Late recurrence of renal cell carcinoma is not a rare event. In this retrospective study we investigate the clinicopathological features and the outcome of patients treated with sorafenib, sunitinib and pazopanib for late relapsing renal cell carcinoma. Materials and Methods: Data were collected from 21 Italian centers involved in the treatment of metastatic renal cell carcinoma. Late relapse was defined as more than 5 years after initial radical nephrectomy. Results: A total of 2,490 patients were screened and 269 (11{\%}) were included in the study. First line therapy was sunitinib in 190 patients (71{\%}), sorafenib in 58 (21{\%}) and pazopanib in 21 (8{\%}). Median progression-free survival was 20.0 months for sunitinib (95{\%} CI 17.0-25.1), and 14.1 months for sorafenib (95{\%} CI 11.0-29.0) and pazopanib (95{\%} CI 11.2-not reported). On multivariate analysis MSKCC score and metastases to lymph nodes, liver and brain were associated with worst overall survival, while pancreatic metastases were associated with longer survival. Furthermore, age, MSKCC score and brain metastases were associated with worst progression-free survival. Conclusions: Patients with late relapsing renal cell carcinoma seem to present a characteristic pattern of metastatic spread without showing significant differences in terms of progression-free survival among sorafenib, sunitinib and pazopanib.",
keywords = "Carcinoma, Protein-tyrosine kinases, Recurrence, Renal cell, Survival",
author = "Matteo Santoni and Alessandro Conti and Camillo Porta and Giuseppe Procopio and Sternberg, {Cora N.} and Umberto Basso and {De Giorgi}, Ugo and Sergio Bracarda and Mimma Rizzo and Cinzia Ortega and Francesco Massari and Roberto Iacovelli and Lisa Derosa and Cristina Masini and Michele Milella and {Di Lorenzo}, Giuseppe and Francesco Atzori and Maria Pagano and Sebastiano Buti and {De Vivo}, Rocco and Alessandra Mosca and Marta Rossi and Chiara Paglino and Elena Verzoni and Linda Cerbone and Giovanni Muzzonigro and Massimo Falconi and Rodolfo Montironi and Luciano Burattini and Daniele Santini and Stefano Cascinu",
year = "2015",
doi = "10.1016/j.juro.2014.07.011",
language = "English",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma

AU - Santoni, Matteo

AU - Conti, Alessandro

AU - Porta, Camillo

AU - Procopio, Giuseppe

AU - Sternberg, Cora N.

AU - Basso, Umberto

AU - De Giorgi, Ugo

AU - Bracarda, Sergio

AU - Rizzo, Mimma

AU - Ortega, Cinzia

AU - Massari, Francesco

AU - Iacovelli, Roberto

AU - Derosa, Lisa

AU - Masini, Cristina

AU - Milella, Michele

AU - Di Lorenzo, Giuseppe

AU - Atzori, Francesco

AU - Pagano, Maria

AU - Buti, Sebastiano

AU - De Vivo, Rocco

AU - Mosca, Alessandra

AU - Rossi, Marta

AU - Paglino, Chiara

AU - Verzoni, Elena

AU - Cerbone, Linda

AU - Muzzonigro, Giovanni

AU - Falconi, Massimo

AU - Montironi, Rodolfo

AU - Burattini, Luciano

AU - Santini, Daniele

AU - Cascinu, Stefano

PY - 2015

Y1 - 2015

N2 - Purpose: Late recurrence of renal cell carcinoma is not a rare event. In this retrospective study we investigate the clinicopathological features and the outcome of patients treated with sorafenib, sunitinib and pazopanib for late relapsing renal cell carcinoma. Materials and Methods: Data were collected from 21 Italian centers involved in the treatment of metastatic renal cell carcinoma. Late relapse was defined as more than 5 years after initial radical nephrectomy. Results: A total of 2,490 patients were screened and 269 (11%) were included in the study. First line therapy was sunitinib in 190 patients (71%), sorafenib in 58 (21%) and pazopanib in 21 (8%). Median progression-free survival was 20.0 months for sunitinib (95% CI 17.0-25.1), and 14.1 months for sorafenib (95% CI 11.0-29.0) and pazopanib (95% CI 11.2-not reported). On multivariate analysis MSKCC score and metastases to lymph nodes, liver and brain were associated with worst overall survival, while pancreatic metastases were associated with longer survival. Furthermore, age, MSKCC score and brain metastases were associated with worst progression-free survival. Conclusions: Patients with late relapsing renal cell carcinoma seem to present a characteristic pattern of metastatic spread without showing significant differences in terms of progression-free survival among sorafenib, sunitinib and pazopanib.

AB - Purpose: Late recurrence of renal cell carcinoma is not a rare event. In this retrospective study we investigate the clinicopathological features and the outcome of patients treated with sorafenib, sunitinib and pazopanib for late relapsing renal cell carcinoma. Materials and Methods: Data were collected from 21 Italian centers involved in the treatment of metastatic renal cell carcinoma. Late relapse was defined as more than 5 years after initial radical nephrectomy. Results: A total of 2,490 patients were screened and 269 (11%) were included in the study. First line therapy was sunitinib in 190 patients (71%), sorafenib in 58 (21%) and pazopanib in 21 (8%). Median progression-free survival was 20.0 months for sunitinib (95% CI 17.0-25.1), and 14.1 months for sorafenib (95% CI 11.0-29.0) and pazopanib (95% CI 11.2-not reported). On multivariate analysis MSKCC score and metastases to lymph nodes, liver and brain were associated with worst overall survival, while pancreatic metastases were associated with longer survival. Furthermore, age, MSKCC score and brain metastases were associated with worst progression-free survival. Conclusions: Patients with late relapsing renal cell carcinoma seem to present a characteristic pattern of metastatic spread without showing significant differences in terms of progression-free survival among sorafenib, sunitinib and pazopanib.

KW - Carcinoma

KW - Protein-tyrosine kinases

KW - Recurrence

KW - Renal cell

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84911434003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911434003&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2014.07.011

DO - 10.1016/j.juro.2014.07.011

M3 - Article

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

ER -